DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Stock Report

Market Cap: US$348.9m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

DiaMedica Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqCM:DMAC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Nov 25BuyUS$944,538Jan StahlbergIndividual113,352US$8.57
25 Nov 25BuyUS$7,631,469Jan StahlbergIndividual1,061,277US$8.57
21 Nov 25BuyUS$1,547,574Jan StahlbergIndividual208,872US$7.41
20 Nov 25BuyUS$951,213Jan StahlbergIndividual128,426US$7.41
19 Nov 25BuyUS$1,732,361Jan StahlbergIndividual240,352US$7.21
18 Nov 25BuyUS$1,234,618Jan StahlbergIndividual182,882US$6.75
17 Nov 25BuyUS$1,221,165Jan StahlbergIndividual187,393US$6.52

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of DMAC?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds3,450,0006.4%
Institutions11,047,32620.5%
General Public14,251,28426.4%
Individual Insiders25,177,08746.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 70.14% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.4%
Jan Stahlberg
8,825,742US$57.1m0%no data
15.6%
Thomas von Koch
8,383,577US$54.2m0%no data
9.2%
Richard Jacinto
4,958,823US$32.1m0%no data
6.4%
Omega Advisors, Inc.
3,450,000US$22.3m70.8%0.67%
4.54%
Leon Cooperman
2,450,000US$15.9m0%no data
4.18%
BlackRock, Inc.
2,252,285US$14.6m21.3%no data
1.85%
Leon & Toby Cooperman Family Foundation
1,000,000US$6.5m0%100.0%
1.66%
Geode Capital Management, LLC
894,115US$5.8m14.6%no data
1.62%
Paragon Associates, Ltd.
875,000US$5.7m0%6.41%
1.57%
Millennium Management LLC
845,309US$5.5m-9.65%no data
1.2%
State Street Investment Management
646,743US$4.2m0.39%no data
1.04%
Vanguard Capital Management, LLC
562,961US$3.6m8.02%no data
0.71%
Bleichroeder LP
382,317US$2.5m0%0.44%
0.63%
Osaic Wealth, Inc.
338,107US$2.2m5.77%no data
0.61%
Northern Trust Global Investments
327,518US$2.1m-3.25%no data
0.47%
Vanguard Portfolio Management, LLC
251,671US$1.6m23.7%no data
0.43%
LPL Financial LLC
233,500US$1.5m3.3%no data
0.39%
R. Giuffre
210,038US$1.4m-38.2%no data
0.29%
John Fichthorn
153,983US$996.3k0%no data
0.27%
Citadel Advisors LLC
145,870US$943.8k0.1%no data
0.27%
Squarepoint OPS LLC
145,247US$939.8k0%no data
0.26%
The Goldman Sachs Group, Inc.
140,750US$910.7k223%no data
0.24%
Dietrich Pauls
128,791US$833.3k92.7%no data
0.22%
BNY Asset Management
117,820US$762.3k6.07%no data
0.19%
Members Wealth LLC
101,382US$655.9k0%0.36%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 17:10
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DiaMedica Therapeutics Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Kyle BauserColliers Securities
Chase KnickerbockerCraig-Hallum Capital Group LLC

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide